drugset / Trial / NCT00756470
Phase II Neoadjuvant in Inflammatory Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to learn how well lapatinib taken alone, followed by taking lapatinib with paclitaxel, and then taking lapatinib with 5-fluorouracil, epirubicin, and cyclophosphamide (FEC75) works to help to control Inflammatory Breast Cancer (IBC). The safety of this drug combination will also be studied.
Timeline
- Start
- 2008-10
- Primary completion
- 2013-10
- Completion
- 2013-10
Outcome
Outcome not reported
Stopped (Enrollment): “Slow accrual.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | 500 mg/m2 | Intravenous |
| Subject | Epirubicin | Small molecule | 75 mg/m2 | Intravenous |
| Subject | Lapatinib | Small molecule | 1000 mg | Oral |
| Subject | Paclitaxel | Small molecule | 80 mg/m2 | Intravenous |
| Subject | fluorouracil | Small molecule | 500 mg/m2 | Intravenous |